Leo puts target on Dupixent in US as FDA clears tralokinumabSanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA Share XLeo puts target on Dupixent in US as FDA clears tralokinumabhttps://pharmaphorum.com/news/leo-puts-target-on-dupixent-in-us-as-fda-clears-tralokinumab/
Pharma group will develop ‘digital endpoint’ for atopic dermatitisThe development of digital medicine requires valid endpoints that can be used in clinical trials, and a consortium Share XPharma group will develop ‘digital endpoint’ for atopic dermatitishttps://pharmaphorum.com/news/pharma-group-will-develop-digital-endpoint-for-atopic-dermatitis/
Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczemaAlready a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category Share XKey drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczemahttps://pharmaphorum.com/news/key-drug-in-sanofis-1-45bn-kymab-buyout-shows-promise-in-eczema/
Pfizer gets first approval, in UK, for Xeljanz follow-up CibinqoPfizer has claimed its first regulatory approval worldwide for Cibinqo, its JAK inhibitor for atopic dermatitis, from the Share XPfizer gets first approval, in UK, for Xeljanz follow-up Cibinqohttps://pharmaphorum.com/news/pfizer-gets-first-approval-in-uk-for-xeljanz-follow-up-cibinqo/
AbbVie’s Rinvoq cleared in EU for atopic dermatitisThe FDA may be reluctant to trust JAK inhibitors, but the European Commission is more willing, and has Share XAbbVie’s Rinvoq cleared in EU for atopic dermatitishttps://pharmaphorum.com/news/abbvies-rinvoq-is-first-jak-drug-cleared-in-eu-for-atopic-dermatitis/
Look out Dupixent, Lilly’s lebrikizumab is on the marchEli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic Share XLook out Dupixent, Lilly’s lebrikizumab is on the marchhttps://pharmaphorum.com/news/look-out-dupixent-lillys-lebrikizumab-is-on-the-march/
Amgen pays Kyowa $400m upfront for OX40 eczema drugAmgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim Share XAmgen pays Kyowa $400m upfront for OX40 eczema drughttps://pharmaphorum.com/news/amgen-pays-kyowa-400m-upfront-for-ox40-eczema-drug/
Lilly’s Olumiant is first JAK drug backed by NICE for eczemaEli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended Share XLilly’s Olumiant is first JAK drug backed by NICE for eczemahttps://pharmaphorum.com/news/lillys-olumiant-is-first-jak-drug-backed-by-nice-for-eczema/
FDA sets April verdict for Pfizer’s “underestimated” atopic dermatitis drugPfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in Share XFDA sets April verdict for Pfizer’s “underestimated” atopic dermatitis drughttps://pharmaphorum.com/news/fda-sets-april-verdict-for-pfizers-underestimated-atopic-dermatitis-drug/
